17 unknown, 14 recruiting, 8 active not recruiting, 8 completed. 15 Phase 1, 15 Phase 2, 10 Not applicable, 5 Phase 3, 2 Early Phase 1.
Follow Gastric Carcinoma: new trials by email Literature Review of Gastric Carcinoma trials Research Report on Gastric Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Learn About the Study Medicine Called PF-08098488 in People With Advanced Solid Tumors. PF-08098488 - Pancreatic Ductal Adenocarcinoma, Esophageal Cancer | Phase 1 | Recruiting | Pfizer | 280 | 2026-10-29 | 2026-10-29 |
| Association Between Microplastic Exposure and the Pathological Progression of Gastric Carcinogenesis Gastric Carcinoma, Gastritis Chronic | Recruiting | Yongquan Shi | 450 | 2026-03-31 | 2026-04-30 | |
| ENPP1/cGAS (EG) and FAP Expression Profiles in Solid Tumors: An Immunohistochemical Study in a Vietnamese Cohort IHC analysis for ENPP1, cGAS, and FAP expression - HCC - Hepatocellular Carcinoma, CRC (Colorectal Cancer) | Recruiting | Tam Anh Research Institute | 162 | 2026-03-19 | 2026-10-26 | |
| Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays PAGODA algorithm, Oxaliplatin, Folinic Acid - Ampulla of Vater Carcinoma, Appendix Carcinoma | Not applicable | Recruiting | Alliance for Clinical Trials in Oncology | 420 | 2026-02-13 | 2026-10-28 |
| A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. Disitamab Vedotin, Tislelizumab, CAPOX (oxaliplatin/capecitabine) - Gastric Carcinoma | Phase 3 | Recruiting | RemeGen Co., Ltd. | 555 | 2026-01-12 | 2026-09-22 |
| The Clinical Significance of Examining Metastatic Lymph Nodes in Individual Gastric Mesenteries in the Patients With Gastric Cancer Undergoing Gastrectomy Gastric Carcinoma | Recruiting | Jichao Qin | 400 | 2025-10-07 | 2026-03-11 | |
| Detection of Upper Gastrointestinal Tumour Depth and Demarcation Using Systemic Administration of Indocyanine Green During Endoscopic Submucosal Dissection Indocyanine Green (IC-Green), Fluorescence guided identification using indocyanine green - Esophageal Carcinoma, Gastric Carcinoma | Phase 1 / Phase 2 | Recruiting | University Medical Center Groningen | 10 | 2025-09-01 | 2025-08-07 |
| Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers Computed Tomography, Fludeoxyglucose F-18, Gallium Ga 68 FAPi-46 - Anal Carcinoma, Bladder Carcinoma | Phase 1 | Active not recruiting | Jonsson Comprehensive Cancer Center | 30 | 2025-08-01 | 2026-10-20 |
| The Vanguard Study: Testing a New Way to Screen for Cancer Biospecimen Collection, Device Usage, Electronic Health Record Review - Bladder Carcinoma, Breast Carcinoma | Not applicable | Recruiting | National Cancer Institute (NCI) | 24000 | 2025-06-18 | 2026-10-06 |
| A Study of Disitamab Vedotin Combined With Tislelizumab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in HER2-Low Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Disitamab Vedotin+Tislelizumab+Oxaliplatin+Capecitabine, Tislelizumab+Oxaliplatin+Capecitabine - Gastric Carcinoma | Phase 3 | Not yet recruiting | RemeGen Co., Ltd. | 616 | 2025-05-15 | 2025-04-25 |
| A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon, Rectum, Stomach, or Pancreas BI 765049 - Colorectal Carcinoma, Gastric Carcinoma | Phase 1 | Terminated | Boehringer Ingelheim | 14 | 2025-03-28 | 2026-10-27 |
| PET-imaging of Two Vartumabs in Patients With Solid Tumors 89Zr-DFO-N-Suc-F8scFv, 89Zr-DFO-N-Suc-C9scFv, PET/CT scan - Solid Tumor, Colon Carcinoma | Early Phase 1 | Recruiting | Var2 Pharmaceuticals | 32 | 2024-12-10 | 2025-12-29 |
| Risk Assessment Evaluation for Identifying Participants at High Risk for Stomach Cancer Biopsy, Biospecimen Collection, Breath Test - Gastric Carcinoma | Not applicable | Recruiting | City of Hope Medical Center | 240 | 2024-06-27 | 2026-03-13 |
| Exploration of Lymph Node Metastasis and Tumor Deposit in the Posterior Gastric Mesentery for Distal Gastric Cancer distal gastrectomy with D2 lymphadenectomy plus complete mesogastric excision (CME) in gastric cancer - Gastric Carcinoma | Recruiting | Jichao Qin | 200 | 2024-05-01 | 2025-09-02 | |
| Analysis of Tumor Deposit at the Fusion Site of the Right Gastric Mesentery and Left Gastric Mesentery in the Patients With Gastric Cancer Who Received Proximal Gastrectomy In addition to routine diagnosis and treatment, no additional intervention measures were taken. - Gastric Carcinoma | Recruiting | Jichao Qin | 100 | 2024-05-01 | 2025-09-02 | |
| XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies. XNW27011 - Pancreatic Adenocarcinoma Metastatic, Lung Cancer (NSCLC) | Phase 1 / Phase 2 | Active not recruiting | Astellas Pharma Global Development, Inc. | 240 | 2023-07-27 | 2026-08-11 |
| The Correlation Between Blood Concentration of Sintilimab and Efficacy and Adverse Reactions in Patients with Advanced Gastric Cancer Gastric Carcinoma, Gastric Neoplasm | Recruiting | Lin Liu | 112 | 2023-02-17 | 2024-11-25 | |
| Anxiety Before Non-cardiac Surgery in Adults Myoma of Uterus, Colon Cancer | Unknown | RenJi Hospital | 424 | 2022-11-10 | 2023-05-31 | |
| The Influence of Splenic Artery Characteristics in Gastric Cancer Surgery Gastrectomy, Gastric Carcinoma | Active not recruiting | xiaohua li | 176 | 2022-05-22 | 2024-11-08 | |
| Immunohistochemical Evaluation of DNA Methylation and Histone Modification in H. Pylori Associated Gastric Carcinoma Immunohistochemical staining for DNMT1 and EZH2 - Gastric Carcinoma | Unknown | Assiut University | 68 | 2022-05-01 | 2023-04-13 |
Showing 20 of 54. Sign in to see all of them.
Stomach Neoplasms (54) · Colorectal Neoplasms (12) · Pancreatic Neoplasms (12) · Carcinoma, Hepatocellular (10) · Esophageal Neoplasms (10) · Lung Neoplasms (10) · Ovarian Neoplasms (10) · Breast Neoplasms (8) · Carcinoma, Non-Small-Cell Lung (8) · Colonic Neoplasms (7) · Prostatic Neoplasms (7) · Urinary Bladder Neoplasms (7) · Neoplasms (6) · Endometrial Neoplasms (5) · Melanoma (5)
Digestive System Diseases (54) · Digestive System Neoplasms (54) · Gastrointestinal Diseases (54) · Neoplasms by Site (54) · Stomach Diseases (54) · Gastrointestinal Neoplasms (51) · Neoplasms (48) · Neoplasms by Histologic Type (20) · Neoplasms, Glandular and Epithelial (19) · Colonic Diseases (18) · Endocrine Gland Neoplasms (18) · Endocrine System Diseases (18) · Intestinal Diseases (18) · Intestinal Neoplasms (18) · Carcinoma (17)
Capecitabine (6) · Magnetic Resonance Spectroscopy (4) · Oxaliplatin (4) · Specimen Handling (4) · apatinib (4) · Biopsy (2) · FAPI-46 (2) · Fluorodeoxyglucose F18 (2) · Practice Guidelines as Topic (2) · Standard of Care (2) · Trastuzumab (2) · XELOX (2) · tesetaxel (2) · 2-(3-(2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo(f)imidazo(1,2-d)(1,4)oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide (1) · 2C4 antibody (1)
National Cancer Institute (NCI) (4) · City of Hope Medical Center (3) · Jichao Qin (3) · Genta Incorporated (2) · Jonsson Comprehensive Cancer Center (2) · PersonGen BioTherapeutics (Suzhou) Co., Ltd. (2) · RemeGen Co., Ltd. (2) · Seagen Inc. (2) · Alliance for Clinical Trials in Oncology (1) · Anhui Provincial Hospital (1) · Assiut University (1) · Astellas Pharma Global Development, Inc. (1) · Boehringer Ingelheim (1) · China Academy of Chinese Medical Sciences (1) · China Medical University, China (1)
United States (23) · China (22) · Germany (4) · Puerto Rico (4) · Spain (3) · France (2) · Guam (2) · Italy (2) · Netherlands (2) · Australia (1) · Canada (1) · Egypt (1) · Honduras (1) · Singapore (1) · South Korea (1)
Lin Yang, Ph.D. (2) · Andres Forero-Torres, MD (1) · Dajun Deng, Master (1) · Gabriel A. Brooks, MD, MPH (1) · Gooitzen van Dam, MD, PhD (1) · Han Liang, Master (1) · Hong Zhao, Professor (1) · Jacek Pinski, MD (1) · Jae Y Kim (1) · Jaffer Ajani, MD (1) · Jeremie Calais (1) · Jeremie Calais, MD (1) · Jie Li, Professor (1) · Jin Li, MD, PHD (1) · Jinwan Wang, Doctor (1)
PMID 19671846, PMID 23918952, PMID 26542081, PMID 26566136, PMID 26586415, PMID 28054442, PMID 29964324, PMID 31400383, PMID 31431673, PMID 32463741, PMID 33048619, PMID 33763656, PMID 35133871, PMID 35138919, PMID 36351402, PMID 36512649, PMID 37053535, PMID 37322121, PMID 37934000, PMID 38591867, PMID 39035732, PMID 39148307, PMID 39666929, PMID 39693587, PMID 39913886, PMID 40087747, PMID 40865033, PMID 40963055, PMID 41066729, PMID 41101974, PMID 41121171, PMID 41791703, PMID 42077070, PMID 42081171, PMID 42571808
P30CA015704 (2), P30CA033572 (2), 2019 (1), N01CN00042 (1), P30CA014089 (1), P30CA015083 (1), P30CA093373 (1), P30CA138292 (1), U10CA180820 (1), U24CA196172 (1), U54CA233306 (1), UG1CA286954 (1)